TXA127
Phase 2- Indications
- Stem cell engraftment, Ischemia
Company intelligence / Profile preview
Tarix Pharmaceuticals Ltd.
Cambridge, Massachusetts, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company conducted Phase 2 clinical trials for TXA127 in various indications including peripheral blood stem cell engraftment and cord blood transplantation. Their lead product TXA127 received Fast Track Designation from the FDA for Duchenne Muscular Dystrophy.
- Therapeutic areas
- HematologyImmunologyRare DiseasesNeurology
- Modalities
- Peptide-based therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Unigene Laboratories (licensing agreement for Peptelligence technology)
Beyond the preview
Go deeper on Tarix Pharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarix Pharmaceuticals Ltd..